Moderna (MRNA) is a publicly traded Healthcare sector company. As of May 20, 2026, MRNA trades at $48.28 with a market cap of $19.09B and a P/E ratio of -5.92. MRNA moved +5.33% today. Year to date, MRNA is +48.15%; over the trailing twelve months it is +73.25%. Its 52-week range spans $22.28 to $67.96. Analyst consensus is neutral with an average price target of $44.73. Rallies surfaces MRNA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Moderna Underweight with $40 December 2026 Price Target: JPMorgan resumed coverage on 14 large-cap biotech firms and assigned Moderna an Underweight rating with a $40 price target for December 2026, citing financial risks despite oncology progress. The bank highlighted sector-wide pipeline successes, margin expansion potential, and imminent clinical trial catalysts that could reshape growth trajectories.
| Metric | Value |
|---|---|
| Price | $48.28 |
| Market Cap | $19.09B |
| P/E Ratio | -5.92 |
| EPS | $-8.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $67.96 |
| 52-Week Low | $22.28 |
| Volume | 3.87M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.23B |
| Net Income | $-3.19B |
| Gross Margin | 22.11% |
15 analysts cover MRNA: 0 strong buy, 1 buy, 13 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.73.